Mosaic ImmunoEngineering Adds Biotech Veteran to Board

Ticker: CPMV · Form: 8-K · Filed: Jul 25, 2024 · CIK: 836564

Mosaic Immunoengineering INC. 8-K Filing Summary
FieldDetail
CompanyMosaic Immunoengineering INC. (CPMV)
Form Type8-K
Filed DateJul 25, 2024
Risk Levelmedium
Pages1
Reading Time2 min
Sentimentneutral

Sentiment: neutral

Topics: board-appointment, management-change, biotechnology

TL;DR

Mosaic ImmunoEngineering just added Dr. Jonathan Lim, ex-Genentech CEO, to its board. Big pharma experience incoming.

AI Summary

Mosaic ImmunoEngineering Inc. announced on July 23, 2024, the election of Dr. Jonathan Lim to its Board of Directors. Dr. Lim brings extensive experience in the biotechnology and pharmaceutical industries, having previously served as CEO of Genentech and currently as Chairman of the Board of Directors for Gritstone Bio, Inc. His appointment is expected to enhance the company's strategic direction and growth.

Why It Matters

The addition of an experienced director like Dr. Lim could signal a strategic shift or increased focus on growth and development for Mosaic ImmunoEngineering.

Risk Assessment

Risk Level: medium — While Dr. Lim's experience is a positive, the filing itself doesn't contain financial details or operational changes that would significantly alter the company's risk profile.

Key Players & Entities

FAQ

What is the primary reason for Dr. Jonathan Lim's election to the Board of Directors?

Dr. Lim was elected to the Board of Directors to leverage his extensive experience in the biotechnology and pharmaceutical industries, aiming to enhance the company's strategic direction and growth.

What previous leadership roles has Dr. Jonathan Lim held?

Dr. Lim previously served as the Chief Executive Officer of Genentech and currently serves as the Chairman of the Board of Directors for Gritstone Bio, Inc.

When was Dr. Jonathan Lim elected to the Board of Directors?

Dr. Jonathan Lim was elected to the Board of Directors on July 23, 2024.

What is Mosaic ImmunoEngineering Inc.'s primary business?

Mosaic ImmunoEngineering Inc. is in the business of Biological Products (No Diagnostic Substances).

What is the filing date of this 8-K report?

This 8-K report was filed on July 25, 2024.

Filing Stats: 448 words · 2 min read · ~1 pages · Grade level 12.1 · Accepted 2024-07-25 08:02:11

Filing Documents

02 Departure of Directors or Certain

Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers. On July 23, 2024, Mr. Carlton Johnson notified the Board of Directors (the "Board") of Mosaic ImmunoEngineering, Inc. (the "Company") of his resignation from the Board effective immediately. In connection with his resignation from the Board, Mr. Johnson also resigned from all committees of the Board of Directors on which he served, including the Audit Committee and Compensation Committee of the Board. Mr. Johnson's resignation is not due to any disagreement with the Company on any matter relating to the Company's operations, policies or practices. 2

SIGNATURES

SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. Mosaic ImmunoEngineering, Inc. Date: July 25, 2024 By: /s/ Steven King Steven King President and Chief Executive Officer, Director 3

View Full Filing

View this 8-K filing on SEC EDGAR

View on Read The Filing